Stockreport

ArriVent BioPharma: Its Leading Asset Furmonertinib Supports A Cautious Buy [Seeking Alpha]

Nuvation Bio Inc. Class A  (NUVB) 
PDF AVBP's strategy targets niche EGFR mutations—exon 20 insertions, PACC, and others—where competition is less entrenched and regulatory pathways are more navigable. Fur [Read more]